araag2/HINT huggingface dataset:
Clinical trial NCT00104650 (phase 2, status: completed)
Conditions: bone metastases in men with hormone-refractory prostate cancer, bone metastases in subjects with advanced breast cancer, bone metastases in subjects with advanced cancer or multiple myeloma
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: iv bisphosphonate q 4 weeks
SMILES: CC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients at least 18 years of age with histologically confirmed solid tumor carcinomas
             (except lung) or multiple myeloma

          -  Radiographic evidence of 1 or more bone lesions or lytic lesion in myeloma

          -  Currently receiving IV bisphosphonates

          -  Urinary N-Telopeptide (uNTx) greater than 50 nM BCE/mM creatinine

          -  Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2

        Exclusion Criteria:

          -  More than 2 prior skeletal related events (SRE)

          -  Known brain metastases

          -  Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

          -  Active dental or jaw conditions which requires oral surgery

          -  Non-healed dental/oral surgery

          -  Prior administration of AMG 162

          -  Evidence of impending fracture in weight bearing bones

          -  Pregnancy or breastfeeding. Subjects must be surgically sterile, postmenopausal, or
             must agree to use effective contraception during the study.
Clinical trial NCT01568216 (phase 2, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: amg 747, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    toxic epidermal necrolysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
             Text Revision (DSM-IV-TR) schizophrenia

          -  Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥20

          -  Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30

          -  Receiving stable antipsychotic therapy for at least 8 weeks prior to screening

          -  Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to
             screening

          -  Subject has had a stable residence or living arrangement for at least 8 weeks prior to
             screening and the residence or living arrangement is not anticipated to change for the
             duration of the study

          -  The subject or subject's legally acceptable representative has provided informed
             consent.

        Exclusion Criteria:

          -  Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive
             disorder, evidence of mental retardation by history or clinical examination or known
             premorbid IQ ≤ 70

          -  Clinically significant suicidal ideation or suicide attempts, assaultive behavior or
             marked changes in mood within the 8 weeks prior to screening, or currently endorsing
             suicidal ideation in clinical exam

          -  Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks
             prior to screening, or during screening

          -  Substance dependence (with the exception of nicotine or caffeine dependence) within
             the 6 months prior to screening, or during screening

          -  Planning to initiate a smoking cessation therapy or otherwise substantially modify
             nicotine use during the study

          -  Positive urine drug test for substances of abuse (with the exception of positive
             screens for prescribed agents such as benzodiazepines).

          -  Other criteria may apply
Clinical trial NCT00071188 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: zd6474, paclitaxel, carboplatin
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  18 years or older

          -  Histologically or cytologically confirmed locally advanced or metastatic NSCLC

          -  No prior chemotherapy/biological therapy/radiation therapy

          -  One or more measurable lesions

          -  Life expectancy more than 12 weeks

        Exclusion Criteria:

          -  Brain metastases or spinal cord compression

          -  Currently active skin disease

          -  History of significant hemoptysis

          -  Abnormal blood chemistry

          -  Cardiac abnormalities

          -  Recent significant cardiac event

          -  Coexisting malignancies
Clinical trial NCT00424229 (phase 2, status: unknown status)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years at the time of signing the informed consent form

          -  MDS with IPSS scores Int-2 or high with deletion 5q(31)

          -  Prior thalidomide allowed

          -  Documented diagnosis of MDS (RA, RARS, RAEB, RAEB-T and CMML with WBC < 13,000/mm3
             according to FAB classification) that meets IPSS criteria for intermediate-2 or
             high-risk disease and has an associated del 5q[31] (the deleted chromosomal region
             must include 5q[31]), with or without additional cytogenetic abnormalities

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Prior therapy with lenalidomide

          -  MDS with IPSS scores low or Int-1

          -  Clinical neuropathy of greater than grade 2

          -  Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML)

          -  Recombinant human erythropoietin (rHuEPO) therapy received within 28 days

          -  Use of androgens other than for treating hypogonadism
Clinical trial NCT00663169 (phase 2, status: completed)
Conditions: arthritis, gouty
ICD codes: A01.04, A02.23, A39.83, A39.84, A54.42, B06.82, B26.85
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  score over 50 on the 0-100 VAS pain scale

          -  acute, confirmed gout flare for no longer than 3 days

        Exclusion Criteria:

          -  Treatment with biological anti-tumor necrosis factor (anti-TNF) within the past 3
             months

          -  Anti-inflammatory medication for the treatment of acute gout within the previous 24
             hours

          -  Pregnant or breastfeeding women

          -  Major surgery with high infection risk

          -  History of severe allergy to food or drugs

          -  History or risk of tuberculosis

          -  Active infection

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00246974 (phase 2, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: gemcitabine, cisplatin, gefitinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically-confirmed transitional cell carcinoma of the
             urothelium

          -  Locally advanced or metastatic disease

          -  At least one measurable lesion as defined by RECIST

          -  Chemotherapy-naiv

        Exclusion Criteria:

          -  Previous chemotherapy or other systemic antitumour therapy

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma, cervical cancer in situ or locally limited
             prostate cancer
Clinical trial NCT01651143 (phase 2, status: completed)
Conditions: systemic sclerosis
ICD codes: M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2
Drugs: sar100842, placebo (for sar100842)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria :

        - Patients who meet the American College of Rheumatology (ACR) criteria for systemic
        sclerosis with diffuse cutaneous involvement and <36 months since the onset of the first
        systemic sclerosis manifestation other than Raynaud's phenomenon and have a Modified Rodnan
        Skin Score (mRSS) ≥ 15 and an area of definite involvement of the dorsal forearm that is
        considered amenable to repeated 4mm skin biopsies.

        Exclusion criteria:

          1. Patients with high dose or unstable low dose immunosuppressive drugs, cytotoxic,
             anti-fibrotic or glucocorticoids drugs at least 4 weeks prior to screening

          2. Serum creatinine > 2.0 mg/dL

          3. Gastrointestinal involvement preventing oral administration of study drug

          4. Severe cardiac and/or pulmonary disease

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00483756 (phase 2, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: cyclosporine, cp-690,550, cp-690,550
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  Recipient of a first-time kidney transplant

          -  Between the ages of 18 and 70 years, inclusive

        Exclusion Criteria:

          -  Recipient of any non-kidney transplant
Clinical trial NCT00204776 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine and oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  preserved organ function

          -  good performance status

          -  no more than one prior therapy

          -  no active brain metastasis

        Exclusion Criteria:

          -  No prior capecitabine or oxaliplatin

          -  no con-current therapy
Clinical trial NCT00548925 (phase 2, status: completed)
Conditions: diabetic neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: abt-894, placebo
SMILES: ClC1=C(Cl)N=CC(=C1)N1C[C@@H]2CN[C@@H]2C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, age 18 to 75

          -  If female, must be of non-childbearing potential or practicing birth control

          -  Has diabetes mellitus (Type 1 or 2) and a diagnosis of painful distal symmetric
             diabetic polyneuropathy

          -  Has had pain from distal symmetric diabetic polyneuropathy for a minimum of 6 months

          -  Must be willing to washout of all analgesic medications prior to entry into the study

        Exclusion Criteria:

          -  Has other conditions that may cause pain

          -  Currently receiving analgesic medications for conditions other than diabetic
             neuropathic pain

          -  Has a history of certain psychiatric diseases

          -  Has a history of certain heart or cardiovascular conditions

          -  Has any clinically significant recent infection, injury, or illness

          -  Current participation in another clinical study or participation within the past 30
             days

          -  Is incapacitated, bedridden or confined to a wheelchair

          -  Is pregnant and/or breastfeeding

          -  Previous participation in this study or any other study with this investigational
             product.
Clinical trial NCT01128179 (phase 2, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: lanthanum carbonate, placebo
SMILES: [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects meeting all of the criteria listed below may be included in the study:

          1. ≥18 years old.

          2. Male, or non-pregnant, non-lactating females who agree to comply with any applicable
             contraceptive requirements of the protocol.

          3. Been in the care of a physician for CKD for >2 months, and are not expected to begin
             dialysis for at least 6 months.

          4. Screening serum c-terminal FGF23 > 50.0RU/mL.

          5. Screening estimated glomerular filtration rate (eGFR) of 30-59mL/min/1.73m2 using the
             MDRD formula.

          6. Normal serum phosphate (0.808-1.55mmol/L).

          7. Endogenous 25-hydroxy Vitamin D levels >20ng/mL.

          8. Adequate protein diet (includes 2-3 portions of protein-rich food per day).

          9. An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

         10. Ability to provide written, signed, and dated (personally) informed consent to
             participate in the study.

        Exclusion Criteria

          1. Vitamin D supplementation required.

          2. Compounds containing calcium, phosphate, aluminium or magnesium required.

          3. Acute renal failure.

          4. Rapidly progressing glomerulonephritis.

          5. Vegetarian diet.

          6. Known allergy to iodine.

          7. Clinically significant uncontrolled concurrent illness, which, in the opinion of the
             Investigator, would impair subjects' ability to give informed consent or take part in
             or complete this clinical study.

          8. Cirrhosis or other clinically significant liver disease (aspartate transaminase (AST)
             or alanine transaminase (ALT) >3 times the upper limit of normal or bilirubin >2 times
             the upper limit of normal).

          9. Past (treated within the last 5 years) or present GI disorders including uncontrolled
             peptic ulcer, Crohn's disease (or other conditions where the integrity of the GI tract
             may be compromised), malignancy, or GI bleed within the last 6 months.

         10. Life-threatening malignancy or current multiple myeloma.

         11. Known to be Human Immunodeficiency Virus (HIV) positive.

         12. History of poor compliance with diet or medication that in the Investigator's opinion
             may interfere with adherence to the protocol.

         13. History of alcohol or other substance abuse within 6 months prior to screening.

         14. Subjects must not have used another investigational medicinal product or taken part in
             a clinical trial within the last 30 days prior to enrolment.

         15. Subjects who have previously been enrolled into this study and subsequently withdrawn.
Clinical trial NCT01039025 (phase 2, status: completed)
Conditions: myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: topotecan, cyclophosphamide, melphalan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with intermediate or high tumor mass multiple myeloma with responsive or
             primary refractory disease; and patients with responsive or refractory relapse.

          2. Physiological age </= 70.

          3. Zubrod performance status < 3.

          4. Life expectancy greater than 12 weeks.

          5. Left ventricular ejection fraction >/= 50%.

          6. No uncontrolled arrythmias or symptomatic cardiac disease.

          7. FEV1, FVC and DLCO >/= 50%.

          8. No symptomatic pulmonary disease.

          9. Serum creatinine < 1.5 mg/dL.

         10. Serum bilirubin < 2x upper limit of normal.

         11. No evidence of chronic or active hepatitis or cirrhosis.

         12. Patient is not pregnant.

         13. Patients or guardian able to sign informed consent.

         14. No active CNS disease.

         15. Platelet count > 100K.

        Exclusion Criteria:

        1) N/A
Clinical trial NCT01312961 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: dupilumab, placebo (for dupilumab), fluticasone/salmeterol combination therapy, fluticasone monotherapy, albuterol, levalbuterol
SMILES: CCO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C
Eligibility criteria:

        Inclusion criteria:

        Medical diagnosis of persistent asthma for at least 12 months whose:

          -  airway inflammation likely to be eosinophilic,

          -  asthma partially controlled or uncontrolled on ICS plus LABA therapy.

          -  On a stable dose of either Fluticasone/Salmeterol, Budesonide/Formoterol,
             Mometasone/Formoterol combination therapy for at least 1 month prior to screening.

          -  Signed an Informed Consent Form and Health Insurance Portability and Accountability
             Act (HIPAA) Authorization Form.

        Exclusion criteria:

          -  Less than 18 years or greater than 65 years of age.

          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further evaluation.

          -  Chronic obstructive pulmonary disease and/or other lung diseases impairing Pulmonary
             Function Tests.

          -  Beta-adrenergic receptor blockers required for any reason.

          -  Current smoker or cessation of smoking within the 6 months prior to screening.

          -  Previous smoking with a smoking history >10 cigarette pack/years.

          -  Participation in another study within 6 months prior to screening if the study
             medication was an antibody or within 30 days prior to screening for all other study
             medications.

          -  Known or suspected non-compliance, alcohol or drug abuse.

          -  Inability to follow the procedures of the study (e.g, due to language problems,
             psychological disorders).

          -  Concomitant severe diseases or diseases for which the use of ICS or LABA were
             contraindicated.

          -  Known allergy to doxycycline or related compounds.

          -  Pregnancy or intention to become pregnant during the course of the study, breast
             feeding, or unwillingness to use a highly effective method of contraception throughout
             the study in women of childbearing potential.

          -  Recent history of a parasitic infection or travel to a parasitic endemic area within 6
             months prior to screening.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00610649 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: mk-8777, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female who is non-pregnant, nonlactating, using an acceptable method of birth control,
             or is not of child-bearing potential;

          -  be diagnosed with current major depressive disorder either mild or severe, as
             evidenced by a score of at least 9 but not more than 20 on the Quick Inventory of
             Depression Symptomatology - Clinician Rated (QIDS-C);

          -  be anti-depressant naïve;

          -  be able to refrain from all use of grapefruit containing products from the time of
             admission until the last assessment is performed at discharge;

          -  smokes less than or equal to 10 cigarettes or equivalent daily.

        Exclusion Criteria:

          -  has any current and primary Axis I disorder other than major depressive disorder;

          -  has any history of bipolar I or II disorder, dysthymia, psychotic depression,
             psychotic disorders, posttraumatic stress disorder, borderline personality disorder,
             obsessive compulsive disorder, or eating disorder;

          -  the duration of the current depressive episode is longer than 2 years at screening;

          -  has any history of a significant suicide attempt, or poses a current risk of
             attempting suicide;

          -  is known to be human immunodeficiency virus (HIV) positive, or positive for hepatitis
             B surface antigen or hepatitis A antibodies or hepatitis C total antibodies;

          -  has any clinically significant concurrent endocrine, renal, respiratory,
             cardiovascular, hematological, immunological, cerebrovascular, neurological,
             malignancy, or any other concurrent medical condition, or has any history of diabetes
             mellitus;

          -  donation of blood within 60 days prior to the anticipated first dose of trial
             medication.